AGN has been the subject of several other research reports. Barclays started coverage on Allergan in a research report on Tuesday. They set an underweight rating and a $133.00 target price for the company. ValuEngine lowered Allergan from a sell rating to a strong sell rating in a research report on Tuesday. Royal Bank of Canada set a $140.00 target price on Allergan and gave the company a hold rating in a research report on Thursday, May 30th. Goldman Sachs Group started coverage on Allergan in a research report on Tuesday, May 28th. They set a neutral rating and a $154.00 target price for the company. Finally, SunTrust Banks dropped their target price on Allergan from $178.00 to $170.00 and set a buy rating for the company in a research report on Friday, May 10th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $178.05.
AGN traded down $3.76 on Monday, hitting $122.85. The company had a trading volume of 2,516,330 shares, compared to its average volume of 2,586,623. The firm has a market cap of $41.67 billion, a P/E ratio of 7.36, a P/E/G ratio of 1.16 and a beta of 1.39. Allergan has a 12-month low of $120.68 and a 12-month high of $197.00. The company has a current ratio of 0.71, a quick ratio of 0.60 and a debt-to-equity ratio of 0.32.
Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, May 7th. The company reported $3.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.55 by $0.24. The company had revenue of $3.60 billion during the quarter, compared to analyst estimates of $3.55 billion. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The firm’s revenue was down 2.0% on a year-over-year basis. During the same quarter last year, the business posted $3.74 earnings per share. On average, research analysts forecast that Allergan will post 16.68 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Tuesday, May 14th will be issued a $0.74 dividend. The ex-dividend date is Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.41%. Allergan’s payout ratio is 17.74%.
A number of large investors have recently modified their holdings of AGN. Liberty Wealth Management LLC raised its stake in Allergan by 108.8% in the first quarter. Liberty Wealth Management LLC now owns 190 shares of the company’s stock worth $27,000 after buying an additional 99 shares in the last quarter. Legacy Bridge LLC bought a new position in Allergan in the first quarter worth approximately $27,000. Patriot Financial Group Insurance Agency LLC raised its stake in Allergan by 2,162.5% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 181 shares of the company’s stock worth $27,000 after buying an additional 173 shares in the last quarter. Investors Research Corp bought a new position in Allergan in the first quarter worth approximately $29,000. Finally, JNBA Financial Advisors bought a new position in Allergan in the fourth quarter worth approximately $30,000. 80.29% of the stock is owned by institutional investors.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
See Also: What is Compound Interest?
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.